Avoro Capital Advisors LLC
Q3 2023 13F-HR Holdings
Net value change ($000)
-959,982
(-13.0%)
New positions
7
Sold out positions
5
Turnover %
9.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Horizon Therapeutics Public Ltd Co | 89,880 | 12.5% |
| Mirati Therapeutics, Inc. | 89,678 | 44.7% |
| GPCR | 50,420 | NEW |
| CymaBay Therapeutics, Inc. | 40,788 | 36.2% |
| Seagen Inc. | 34,646 | 10.2% |
| AKRO | 28,100 | NEW |
| MLTX | 26,025 | 29.6% |
| RCKT | 25,613 | NEW |
| ASND | 24,094 | 7.5% |
| Cerevel Therapeutics Holdings, Inc. | 20,860 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| APLS | -589,555 | -58.2% |
| IVERIC bio, Inc. | -316,687 | -100.0% |
| MDGL | -122,908 | -35.1% |
| DICE Therapeutics, Inc. | -102,181 | -100.0% |
| SRPT | -42,075 | -7.9% |
| KYMR | -35,041 | -39.5% |
| ALNY | -30,816 | -14.7% |
| NUVL | -30,121 | -44.6% |
| DSGN | -22,050 | -100.0% |
| XENE | -21,266 | -11.3% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
1,220
(0.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|